Format

Send to

Choose Destination
J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924.

Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.

Author information

1
McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada.
2
Department of Neurology, National Neuroscience Institute, Singapore.
3
Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Abstract

Cautious optimism is appropriate for a near future (five years) time frame for a number of drugs acting on the different pathophysiological components of Alzheimer's disease (amyloid deposition, tau hyperphosphorylation, neuroinflammation, vascular changes, to name the most important known so far). Since the relative weight of these components will be different between individuals and will even change over time for each individual, a 'one drug fit for all' approach is no longer defensible. Precision medicine using biomarkers in the diagnosis and treatment of Alzheimer's disease is the new strategy.

KEYWORDS:

Alzheimer’s disease; biomarkers; brain imaging; database analysis; diagnosis; human volunteer cohorts; precision medicine; translational research; treatment

PMID:
29504543
PMCID:
PMC6004905
DOI:
10.3233/JAD-179924
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center